Living on the Spectrum cover
Living on the Spectrum

Living on the Spectrum

About

A public-facing conversational podcast exploring autism, ADHD, Sensory Processing Disorder (SPD), Developmental Language Disorder (DLD), and other neurodevelopmental differences. We curate the latest findings from research and community discussions, turning complex information into clear, dual-host dialogues. Our mission is to bridge the gap between clinical labels and real life, highlighting the overlaps and connections within the neurodivergent community.

Listen

A recent Angelman syndrome study found one protein downstream of UBE3A—does that mean treatment is close?

In Angelman syndrome, a single gene loss can slow new protein production in neurons four to five times—and clearing one downstream clog only partly helps. Key threads: UBE3A’s job tagging proteins for recycling ASNS piling up in neurons The integrated stress response halting protein synthesis Partial rescue: movement and clasping improve; sleep and coordination don’t Why mouse and cell data can’t yet change care The partial result is the story: ASNS is one thread, not the whole fabric.

This episode focuses on a single study about Angelman syndrome, UBE3A, and a protein called ASNS. The study was published in Nature, from Jason Yi’s lab at Washington University in St. Louis, and Sarah Thau reported on it for The Transmitter on November 19. The conversation flagged that this is a mouse and cell study, which shapes what can and cannot be taken from it.

Loss of Angelman-linked UBE3A gene triggers stress response in neurons

Angelman syndrome is a genetic condition characterized by epilepsy, developmental delays, intellectual disabilities, and in some cases autism. It is linked to loss of UBE3A. UBE3A codes for an enzyme that tags proteins for degradation; the conversation described it as a labeling system that marks proteins for recycling. UBE3A has more than 50 substrates, and identifying which proteins matter for which symptoms has been an open problem for about 20 years. Rebecca Burdine, a professor of molecular biology at Princeton and chair of the science advisory committee for the Angelman Syndrome Foundation, who was not involved in the study, said enzyme-substrate interactions can be fleeting — like trying to photograph a handshake.

The team used biochemical assays to identify UBE3A substrates, and ASNS — asparagine synthetase, an enzyme that makes the amino acid asparagine — kept appearing near the top. They confirmed ASNS binds to UBE3A in human embryonic kidney cells, and when UBE3A was knocked out, ASNS was not tagged for degradation and accumulated. ASNS is normally found across cells of various tissue types, but in mouse brains it was expressed primarily in neurons. Jason Yi said, “We were very surprised to see that.”

In a mouse model of Angelman syndrome, ASNS was elevated. When it was not degraded, asparagine built up along with phenylalanine, glycine, and proline. That excess triggered the integrated stress response — a cellular stress pathway that dials down new protein production — and halted production of new proteins in neurons. New protein synthesis rates in the Angelman mice were four to five times slower than in wildtype mice, the comparison mice without the Angelman-linked change. The study reports that slower synthesis came alongside reduced brain mass and sparser neuronal packing. The conversation framed these as mechanistic findings in an animal model, not measurements that translate directly to people.

The team then knocked out ASNS as well as UBE3A. This partially improved the rate of protein synthesis and some traits: less adult obesity, less hind-limb clasping (a posture used as a marker in mouse models), and more movement in the open field test (a measure of movement in an open arena). Poor motor coordination and aberrant sleep patterns did not improve. Mark Zylka, a professor of cell biology and physiology at UNC Chapel Hill who was not involved in the study, said, “While there are many UBE3A substrates, this one seems to be fairly important in contributing to many, but not all, of the symptoms that are associated with Angelman syndrome.” Lawrence Reiter at Tulane, also not involved, made a similar point: given the complexity of pathways downstream of UBE3A loss and the fact that the rescue did not fix every symptom in mice, it is unlikely that targeting only one substrate will resolve all of them.

Burdine said addressing UBE3A loss directly requires complex interventions such as gene therapy — “It’s not like you’re going to take a pill and UBE3A is going to reappear.” But if there is a substrate where there is too much or too little, “that starts to get into the realm of a tractable problem.” The conversation noted this is a target, not a treatment. The article also described backstory: Yi was advised not to continue studying UBE3A on the grounds that replacing the paternal copy of UBE3A was already possible as a gene-therapy approach, and the article notes therapeutic progress has been a rocky road.

Limits discussed: the experiments were biochemical assays, human embryonic kidney cells, and a mouse model. The kidney cells are not neurons or people. A mouse model captures some features and not others. The rescue was partial even in mice. The paper has no human trial data, and the conversation said nothing can be concluded from it about effects in people or about dosing, safety, or timing. The discussion also noted that Angelman syndrome is a single-gene condition, but losing the gene has distributed downstream effects across dozens of substrates and multiple pathways; single-gene does not mean single-consequence. Because Angelman syndrome involves autism in some cases, the conversation connected the research to broader questions about labels and overlap. It also noted that mouse measures are proxies; for people, priorities may include sleep, communication, seizures, or comfort, and the study itself showed sleep and coordination did not improve while other traits did.

The conversation said the honest answer for families asking whether this means anything for them yet is “not yet, but it’s not nothing.” It does not change care today, and treatment decisions should be made with clinicians, not from a mouse study. Burdine said a study like this shows there are still other things to explore: “We’re not going to give this up. We’re going to figure this out.”

Podcast Transcript

Aaron: Welcome to Living on the Spectrum. I'm Aaron, and I'm sitting here with Jamie. Today we're doing something a little different — we're spending the whole episode on one piece of research, because it's a really good window into how a single gene change can ripple outward through a cell. It's about Angelman syndrome, and it involves a gene called UBE3A and a protein called ASNS.

Jamie: That's right. The study was published last month in Nature, from Jason Yi's lab at Washington University in St. Louis, and Sarah Thau reported on it for The Transmitter on the 19th of November. It's a mouse and cell study, which I want to flag up front, because that shapes what we can and can't take from it.

Aaron: Let's start with the basics. What is Angelman syndrome?

Jamie: It's a genetic condition characterized by epilepsy, developmental delays, intellectual disabilities and, in some cases, autism. It's linked to UBE3A — the loss of that gene is what causes it.

Aaron: And what does UBE3A normally do?

Jamie: It codes for an enzyme whose job is to tag proteins for degradation. I think of it as a labeling system — it puts a sticker on a protein that says "recycle this," and the cell's machinery clears it away. So it's part of the cell's housekeeping.

Aaron: Which means when it's missing, proteins that should have been cleared out stick around.

Jamie: Exactly, and the hard question has always been: which proteins, and which ones actually matter for symptoms? UBE3A has more than 50 substrates — proteins it can tag. Working out which of those drives which part of the condition has been an open problem for about twenty years.

Aaron: Why is it so hard to pin down?

Jamie: Rebecca Burdine, a professor of molecular biology at Princeton who chairs the science advisory committee for the Angelman Syndrome Foundation — she wasn't involved in the study — explained that an enzyme's interactions with its substrates can be fleeting. So it's a bit like trying to photograph a handshake. By the time you look, the two have let go.

Aaron: And this team used a different approach to catch that handshake.

Jamie: They used a variety of biochemical assays to identify UBE3A substrates, and one kept coming up near the top: ASNS, which stands for asparagine synthetase. That's an enzyme that makes the amino acid asparagine. They confirmed it binds to UBE3A in human embryonic kidney cells — and when they knocked out UBE3A, ASNS didn't get tagged for degradation.

Aaron: So no sticker, and ASNS accumulates.

Jamie: Right. And then there's a detail I found genuinely surprising. ASNS is normally found across cells of various tissue types, but in mouse brains it was expressed primarily in neurons — the nerve cells themselves.

Aaron: And Jason Yi said as much, didn't he?

Jamie: He did. His quote is: "We were very surprised to see that."

Aaron: Okay, so follow the chain from there. What happens when ASNS builds up?

Jamie: In a mouse model of Angelman syndrome, ASNS was elevated. When it wasn't being degraded, asparagine built up along with three other amino acids — phenylalanine, glycine and proline. That excess triggered something called the integrated stress response, and that halted production of new proteins in neurons.

Aaron: Can you unpack the integrated stress response for people who haven't come across it?

Jamie: Think of it as a cellular stress pathway. When it's switched on, the cell dials down production of new proteins. In this study, the amino acid buildup switched it on, and that's what slowed new protein production in neurons.

Aaron: And the numbers here are striking. New protein synthesis rates in the Angelman mice were four to five times slower than in wildtype mice — the comparison mice without the Angelman-linked change.

Jamie: Yes. The study reports that slower synthesis came alongside reduced brain mass and sparser neuronal packing in those mice. I'd frame that as part of the mechanistic story in an animal model — it's not a measurement you can simply translate onto a person.

Aaron: Then comes the part that will interest a lot of families: they tried to intervene downstream. Instead of fixing UBE3A, they knocked out ASNS as well.

Jamie: That's the elegant part of the design. If ASNS is one of the things clogging the works, removing it should relieve some of the pressure without touching the underlying gene. And it did — partially. Knocking out ASNS in the Angelman mice improved the rate of protein synthesis and improved some traits: less adult obesity, less hind-limb clasping, and more movement in the open field test.

Aaron: Hold on. Hind-limb clasping and open field — those are lab terms. What do they actually mean?

Jamie: Hind-limb clasping is a posture where the animal's hind legs clasp together instead of splaying normally, and it's used as a marker in these mouse models. The open field test is basically what it sounds like: an animal is placed in an open arena and researchers measure how much it moves around. So in this case, the ASNS knockout mice moved more, and the clasping was reduced.

Aaron: But not everything improved.

Jamie: Correct — poor motor coordination and aberrant sleep patterns did not improve. That partial result is the most important sentence in the whole story, honestly.

Aaron: Because it tells you ASNS isn't the whole story.

Jamie: It tells you it's an important thread, not the entire fabric. Mark Zylka, a professor of cell biology and physiology at UNC Chapel Hill who wasn't involved in the study, put it this way: "While there are many UBE3A substrates, this one seems to be fairly important in contributing to many, but not all, of the symptoms that are associated with Angelman syndrome." And Lawrence Reiter at Tulane, also not involved, made a similar point — that given the complexity of the pathways downstream of UBE3A loss, and the fact that the rescue didn't fix every symptom in mice, it's unlikely that targeting only one substrate will resolve all of them.

Aaron: That's a really useful corrective, because there's a temptation when you read a headline like this to think: they found the protein, so we're close to a fix.

Jamie: It's understandable, and I'd say the independent researchers quoted in the article are cautious about that. Burdine made a point I found clarifying. She said addressing UBE3A loss directly requires complex interventions like gene therapy — "It's not like you're going to take a pill and UBE3A is going to reappear." But, she said, if there's a substrate where there's too much or too little, "that starts to get into the realm of a tractable problem."

Aaron: So the value here isn't a treatment, it's a target. Something you could conceivably design an intervention around.

Jamie: That's how I read it. Though — and this is important — being tractable in principle is a long way from a therapy in a clinic. There's no human trial data in this paper at all.

Aaron: There's also a bit of backstory in the article about the advice Yi got when he started his lab. He was advised not to continue studying UBE3A, on the grounds that it was already possible to replace the paternal copy of UBE3A as a gene-therapy approach to Angelman syndrome.

Jamie: Yes, and the article notes that therapeutic progress has been a rocky road. I think that's the honest context. The genetic fix is the more direct idea, and it's genuinely hard to deliver. Which is why finding a downstream piece of the puzzle is worth doing even while gene therapy work continues.

Aaron: Let's be precise about what this study can and can't support. The experiments were biochemical assays, human embryonic kidney cells, and a mouse model.

Jamie: Right. The kidney cells are a workhorse system for testing whether two proteins bind — they're not neurons, and they're not people. And a mouse model of a human condition is a model; it captures some features and not others. So the mechanism is well supported in that system, and the rescue is partial even there. We can't say anything from this about what would happen in a person, or about dosing, safety, timing — none of that is in this paper.

Aaron: And there's a broader thing I keep coming back to as I read this stuff. Angelman is a single-gene condition — one gene with a clear link. And even here, the downstream picture branches out into dozens of substrates and multiple pathways.

Jamie: That's a fair reading. Single-gene doesn't mean single-consequence. The gene has one clear identity; the effects of losing it are distributed. That's a theme across developmental conditions generally, and it's why "we found the gene" and "we understand the condition" are very different statements.

Aaron: Which connects to what we talk about on this show all the time — the way labels overlap. The article notes that Angelman syndrome involves autism in some cases. So families in our audience may be following this research even if their own child's diagnosis is different, because the questions rhyme: what's driving what, and what's actually worth intervening on?

Jamie: And that last part is a genuinely open conversation, not just a scientific one. A mouse measure like open-field movement is a proxy for something researchers care about, but for a person, what matters might be sleep, or communication, or seizures, or comfort. Those aren't the same list, and the study itself shows the lists don't line up — sleep and coordination didn't budge while other traits did.

Aaron: So if a family reads about this and asks, "does this mean anything for us yet?" — the honest answer is not yet, but it's not nothing either.

Jamie: I'd say it's a solid mechanistic finding in a field where the mechanism has been stubbornly hard to get at, and it identifies a candidate worth pursuing. It doesn't change care today. Anyone making decisions about treatment should be talking to their own clinicians, not to a mouse study.

Aaron: The other thing I took from the article was Burdine's tone at the end. She said a study like this one says there are still other things to explore — "We're not going to give this up. We're going to figure this out."

Jamie: I liked that too. It's a researcher saying the problem is hard and the work continues, not that the door is closed. And that's an honest place to land with science like this — real progress, real limits, and more work underway.

Aaron: That's where we'll leave it. Thanks for sitting with one paper with us — it's a format we'd like to do more often when something substantial lands. The original article and study details are on the episode page, so you can read it yourself. Thanks for listening, and we'll see you next time.

Jamie: Take care, everyone.

References